Trending Stock News

First Midwest Bank Trust Division Cut Sempra Energy (SRE) Position; Shorts at Novartis AG (NVS) Raised By 2.17%

Novartis AG (NYSE:NVS) Logo

First Midwest Bank Trust Division decreased Sempra Energy (SRE) stake by 20.05% reported in 2018Q1 SEC filing. First Midwest Bank Trust Division sold 3,073 shares as Sempra Energy (SRE)’s stock declined 3.94%. The First Midwest Bank Trust Division holds 12,254 shares with $1.36 million value, down from 15,327 last quarter. Sempra Energy now has $29.87 billion valuation. The stock increased 0.47% or $0.53 during the last trading session, reaching $113.09. About 2.94 million shares traded or 25.74% up from the average. Sempra Energy (NYSE:SRE) has declined 8.17% since June 22, 2017 and is downtrending. It has underperformed by 20.74% the S&P500. Some Historical SRE News: 09/03/2018 – Sempra Dreams of Electric Cars in Oil-Rich Texas With Oncor; 07/05/2018 – SEMPRA HAS $4B NET OPERATING LOSSES FOR TAXES; 12/03/2018 – Sempra Energy: Board Appoints J. Walker Martin as CEO, Joseph A. Householder as President, Both Effective May 1; 28/03/2018 – SoCalGas Helps Fleet Owners Put New Near-Zero Emissions Natural Gas Trucks on the Road; 08/03/2018 – TEXAS REGULATORS APPROVE SEMPRA ENERGY’S MAJORITY OWNERSHIP OF; 07/05/2018 – SEMPRA ENERGY 1Q EARNINGS CALL BEGINS; 10/04/2018 – SEMPRA ENERGY ALSO NAMES JOSEPH HOUSEHOLDER COO; 12/03/2018 – Sempra Energy Also Appoints Martin as New Member of Board Effective May 1; 17/05/2018 – SoCalGas Introduces Innovative New Solar Hydrogen Generation System at California Air Resources Board Symposium; 07/05/2018 – SEMPRA 1Q EARNINGS CALL ENDS

Novartis AG (NYSE:NVS) had an increase of 2.17% in short interest. NVS’s SI was 1.46 million shares in June as released by FINRA. Its up 2.17% from 1.43M shares previously. With 1.64M avg volume, 1 days are for Novartis AG (NYSE:NVS)’s short sellers to cover NVS’s short positions. The SI to Novartis AG’s float is 0.07%. The stock decreased 0.34% or $0.25 during the last trading session, reaching $73.98. About 1.10 million shares traded. Novartis AG (NYSE:NVS) has declined 6.45% since June 22, 2017 and is downtrending. It has underperformed by 19.02% the S&P500. Some Historical NVS News: 16/05/2018 – NOVARTIS AG NOVN.S CFO SAYS SAYS HAS THE SIZE, THERAPEUTIC AREAS THAT NOVARTIS NEEDS TO BE SUCCESSFUL, SEES NO “DOMINO EFFECT” OF OTHER DRUG DEALS THAT WOULD FORCE NOVARTIS INTO LARGE-SCALE ACQUSITIO…; 20/04/2018 – #3 Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies $NVS; 04/04/2018 – NOVARTIS GAINED CHF216M FROM SWISS PENSION LAW CHANGE: HZ; 09/04/2018 – Novartis bets on gene therapy with $8.7bn deal to buy US group AveXis; 11/05/2018 – FDA Granted Approval of Gilenya to Novartis; 27/03/2018 – #2 Reshaping Novartis into a more aggressive pharma giant, Vas Narasimhan bags a $13B consumer sale ahead of bolt-on deals $NVS $GSK; 17/05/2018 – FDA’S GOTTLIEB – COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE ASTRAZENECA LP, ACORDA THERAPEUTICS, MYLAN PHARMA, NOVARTIS PHARMA; 10/04/2018 – MOODY’S SAYS MONETISING VALUE OF JV STAKE HAS REDUCED DIVERSITY BUT INCREASED CASH BALANCES, AND LEFT UNCERTAINTY OVER USE OF PROCEEDS; 16/05/2018 – Had some interesting unsubscribes from $NVS today — the price of independence. @VasNarasimhan; 19/03/2018 – NOVARTIS SAYS THE PATENT IN QUESTION DATES FROM 1997 AND IS CALLED ‘VECTOR FOR EXPRESSION OF A POLYPEPTIDE IN A MAMMALIAN CELL’

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company has market cap of $190.91 billion. The companyÂ’s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. It has a 21.69 P/E ratio. This divisions also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies.

More notable recent Novartis AG (NYSE:NVS) news were published by: Seekingalpha.com which released: “Novartis: Exit Sandoz US Now” on June 06, 2018, also Seekingalpha.com with their article: “Novartis’ Kymriah shows sustained benefit in DLBCL patients” published on June 18, 2018, Streetinsider.com published: “Novartis (NVS) Granted FDA Approval for Inclusion of New Evidence that Cosentyx (secukinumab) Inhibits Progression …” on June 19, 2018. More interesting news about Novartis AG (NYSE:NVS) were released by: Prnewswire.com and their article: “Developing Technologies for Optical Therapies Aimed At Overcoming Key Challenges in the Healthcare Industry” published on June 21, 2018 as well as Fool.com‘s news article titled: “5 Experimental New Drugs That Could Be Worth $47 Billion” with publication date: June 20, 2018.

Among 17 analysts covering Novartis Ag (NYSE:NVS), 5 have Buy rating, 3 Sell and 9 Hold. Therefore 29% are positive. Novartis Ag had 38 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Hold” rating by Cowen & Co given on Friday, February 2. Cowen & Co maintained Novartis AG (NYSE:NVS) on Monday, July 10 with “Hold” rating. The firm has “Neutral” rating given on Friday, March 24 by JP Morgan. The firm has “Buy” rating by Societe Generale given on Wednesday, March 8. The firm has “Hold” rating by Cowen & Co given on Monday, September 11. On Tuesday, April 12 the stock rating was downgraded by Morgan Stanley to “Underperform”. Leerink Swann maintained Novartis AG (NYSE:NVS) on Thursday, January 25 with “Market Perform” rating. The stock of Novartis AG (NYSE:NVS) has “Market Perform” rating given on Wednesday, March 23 by Leerink Swann. On Monday, October 10 the stock rating was maintained by Chardan Capital Markets with “Buy”. The firm has “Hold” rating by Leerink Swann given on Thursday, June 22.

First Midwest Bank Trust Division increased Netflix Inc (NASDAQ:NFLX) stake by 2,316 shares to 9,270 valued at $2.74M in 2018Q1. It also upped Ishares Tr (MTUM) stake by 38,599 shares and now owns 57,492 shares. Dbv Technologies S A was raised too.

Analysts await Sempra Energy (NYSE:SRE) to report earnings on August, 3. They expect $1.22 earnings per share, up 10.91% or $0.12 from last year’s $1.1 per share. SRE’s profit will be $322.24 million for 23.17 P/E if the $1.22 EPS becomes a reality. After $1.43 actual earnings per share reported by Sempra Energy for the previous quarter, Wall Street now forecasts -14.69% negative EPS growth.

Since April 5, 2018, it had 0 insider purchases, and 3 selling transactions for $6.14 million activity. 1,918 shares valued at $201,006 were sold by OUCHI WILLIAM G on Wednesday, May 9. On Thursday, April 5 ROWLAND G JOYCE sold $433,530 worth of Sempra Energy (NYSE:SRE) or 3,948 shares. Shares for $5.51M were sold by REED DEBRA L.

Among 11 analysts covering Sempra Energy (NYSE:SRE), 6 have Buy rating, 0 Sell and 5 Hold. Therefore 55% are positive. Sempra Energy had 27 analyst reports since September 15, 2015 according to SRatingsIntel. As per Tuesday, March 6, the company rating was maintained by JP Morgan. Wells Fargo maintained the stock with “Outperform” rating in Tuesday, October 10 report. The stock of Sempra Energy (NYSE:SRE) has “Buy” rating given on Wednesday, January 3 by Wells Fargo. BMO Capital Markets maintained it with “Hold” rating and $115 target in Thursday, May 11 report. The company was maintained on Friday, August 4 by BMO Capital Markets. The firm earned “Outperform” rating on Wednesday, February 28 by Wells Fargo. RBC Capital Markets maintained Sempra Energy (NYSE:SRE) rating on Monday, January 25. RBC Capital Markets has “Outperform” rating and $116 target. Barclays Capital downgraded Sempra Energy (NYSE:SRE) on Thursday, June 8 to “Equal-Weight” rating. The company was maintained on Wednesday, November 1 by JP Morgan. RBC Capital Markets maintained Sempra Energy (NYSE:SRE) on Sunday, August 27 with “Buy” rating.

More recent Sempra Energy (NYSE:SRE) news were published by: Benzinga.com which released: “Wells Fargo Downgrades Sempra Energy After Monday’s Spike On Activist Involvement” on June 12, 2018. Also Seekingalpha.com published the news titled: “California recommends increasing gas storage at Aliso Canyon” on June 19, 2018. Seekingalpha.com‘s news article titled: “Low Energy MLPs” with publication date: June 17, 2018 was also an interesting one.

Investors sentiment decreased to 1 in 2018 Q1. Its down 0.27, from 1.27 in 2017Q4. It turned negative, as 54 investors sold SRE shares while 178 reduced holdings. 63 funds opened positions while 170 raised stakes. 225.19 million shares or 17.16% more from 192.21 million shares in 2017Q4 were reported. Raymond James Fincl Services Advisors Inc has invested 0.01% in Sempra Energy (NYSE:SRE). Cohen Steers Inc invested in 12,170 shares. Metropolitan Life Company stated it has 39,673 shares. Ci Investments Inc holds 1.15% or 894,575 shares in its portfolio. New Mexico Educational Retirement Board invested in 0.1% or 23,941 shares. Karpus Inc accumulated 2,050 shares or 0.01% of the stock. Convergence Investment Prtn invested in 444 shares. Fulton Breakefield Broenniman Ltd Liability Corp holds 0.88% in Sempra Energy (NYSE:SRE) or 45,641 shares. High Pointe Ltd has 1.59% invested in Sempra Energy (NYSE:SRE). Palladium Ltd Limited Liability Company invested 0.05% of its portfolio in Sempra Energy (NYSE:SRE). Service Automobile Association has invested 0.04% of its portfolio in Sempra Energy (NYSE:SRE). Hennessy Incorporated owns 462,340 shares. First Allied Advisory Svcs Incorporated owns 3,118 shares for 0.01% of their portfolio. Vanguard Group reported 0.09% stake. Whittier Company holds 0.03% of its portfolio in Sempra Energy (NYSE:SRE) for 7,788 shares.

Sempra Energy (NYSE:SRE) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *